Secondary brain tumors after cranial radiation therapy: A single-institution study
Secondary brain tumors after cranial radiation therapy: A single-institution study
复制标题
DOI：
10.1016/j.rpor.2020.01.009
复制
发表时间：
2020-03-01
影响因子：
1.2
通讯作者：
Saito, Kiyoshi
中科院分区：
文献类型：
--
作者：
Fujii, Masazumi;Ichikawa, Masahiro;Saito, Kiyoshi
目的：要研究的概率发展继发性脑肿瘤后颅radiotherapy.Background颅放射治疗的患者是在风险发展继发性脑tumors.Patients和方法：我们计划了一个机构调查继发性脑肿瘤的幸存者颅照射后，并回顾了30年的持续时间数据。结果：继发性脑肿瘤占21%，其中海绵状血管瘤占10%，脑膜瘤占6%，颅骨骨瘤占3%，间变性星形细胞瘤占1%。发展中的继发性脑肿瘤的累积比例为6%，在10年和20%，在20年，而发展中的海绵状血管瘤和脑膜瘤的累积比例分别为16%和7%，在20 years，respectively：我们的研究表明，接受颅脑照射的患者有继发性脑肿瘤，如海绵状血管瘤和脑膜瘤的风险。因此，通过每年一次的MRI扫描对有颅脑照射史的癌症幸存者进行细致的随访是合理的。这将有助于临床医生早期发现继发性脑肿瘤，并使其管理更加容易。(C)2020年大波兰癌症中心。Elsevier B. V.出版，保留所有权利。
Aim: To study the probability of developing secondary brain tumors after cranial radiotherapy.Background Patients treated with cranial radiotherapy are at risk for developing secondary brain tumors.Patients and methods: We planned an institutional survey for secondary brain tumors in survivors after cranial irradiation and reviewed the 30-year duration data. Event analysis and cumulative proportion curves were performed to generally estimate the cumulative proportion of developing secondary brain tumors, cavernoma and meningioma at different periods of time.Results: Secondary brain tumors occurred in 21% of cases: 10% were cavernomas, 6% were meningiomas, 3% were skull osteomas, and 1% were anaplastic astrocytoma. The cumulative proportion of developing secondary brain tumor was 6% at 10 years and 20% at 20 years, while the cumulative proportion for developing cavernomas and meningiomas was 16% and 7% at 20 years, respectively.Conclusion: Our study shows that patients who received cranial irradiation were at risk of secondary brain tumors such as cavernomas and meningiomas. Thus, a meticulous follow-up of cancer survivors with history of cranial irradiation by an annual MRI scan is justifiable. This will help clinicians to detect secondary brain tumors early and make its management much easier. (C) 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.